Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergic Conjunctivitis
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®) (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Alcon Research
Summary
The purpose of this study is to evaluate patient perceptions of olopatadine 0. 2% dosed once
daily in patients previously treated with twice-daily, topical, ocular, anti-allergy
medications.
Clinical Details
Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Overall Patient SatisfactionOverall Patient Satisfaction
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 12 years of age or older.
- History (within the past 24 months) of allergic conjunctivitis.
- Active signs and symptoms of ocular allergies.
- Ocular health within normal limits, as determined by the investigator or
subinvestigator.
- Willing to avoid contact lens wear each study visit immediately prior to study
medication instillation and for 10 minutes after instillation of study drug.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Contraindications or hypersensitivity to study medication or its components.
- One sighted eye or not correctable to 0. 6 logMAR or better in both eyes at the
screening visit.
- Known history of recurrent corneal erosion syndrome.
- Ocular trauma or surgical intervention within 6 months prior to Visit 1.
- Participation in any other investigational study within 30 days before Visit 1.
- Pregnant or nursing.
- Other protocol-defined exclusion criteria may apply.
Locations and Contacts
Additional Information
Starting date: June 2010
Last updated: March 5, 2012
|
